title: Androgen excess contributes to altered growth hormone/insulin-like growth factor-1 axis in nonobese women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To investigate the relationship between ovarian androgen excess and impaired growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis in nonobese women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  A prospective, controlled clinical study.
  
  
  METHODS
  Reproductive Endocrine Unit, Department of Obstetrics and Gynecology, Jinling Hospital, Nanjing University School of Clinical Medicine.
  
  
  METHODS
  Six patients with PCOS with both clomiphene resistance and gonadotropin hyperreponsiveness and six controls with regular cycles, matched for age and body mass index (BMI).
  
  
  METHODS
  Bilateral ovarian wedge resection (OWR) was performed to induce ovulation surgically for these refractory women with PCOS. A GH stimulation test with oral L-dopa was arranged for controls and for patients with PCOS before and again 6 months later after OWR.
  
  
  METHODS
  Plasma GH, IGF-1, FSH, LH, testosterone, androstenedione, estradiol, progesterone, prolactin, insulin, and glucose.
  
  
  RESULTS
  Basal levels and areas under the response curve of GH and GH-IGF-1 ratio to L-dopa were significantly lower in patients with PCOS before surgery than those of controls. The OWR in patients with PCOS obviously reduced their androstenedione and testosterone levels and insulin-glucose ratios, and increased the GH and GH-IGF-1 responses to L-dopa.
  
  
  CONCLUSIONS
  Impaired somatotrophic axis caused by a defect in central dopaminergic activity may be responsible for severe anovulation in these women with PCOS, which could be reversed by removing excessive androgens with OWR.
authors.affiliation: University Central Hospital of Turku, Turku, Finland. xiaoke.wu@utufi
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: K
authors.initials: K
authors.lastname: Sallinen
authors.forename: S
authors.initials: S
authors.lastname: Zhou
authors.forename: Y
authors.initials: Y
authors.lastname: Su
authors.forename: P
authors.initials: P
authors.lastname: Pöllänen
authors.forename: R
authors.initials: R
authors.lastname: Erkkola
mesh_terms: D000328:Adult; D000728:Androgens / Q000378:metabolism*; D000735:Androstenedione / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D019382:Human Growth Hormone / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000601:surgery; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000378:metabolism*; D007980:Levodopa / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000097:blood; D009765:Obesity / Q000378:metabolism; D010053:Ovary / Q000601:surgery; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000601:surgery*; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood
chemical_list: D000728:Androgens; D019382:Human Growth Hormone; D013739:Testosterone; D000735:Androstenedione; D007980:Levodopa; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone